RADIONUCLIDE GENERATORS TO PRODUCE THE IRIDIUM-194 BETA EMITTER

用于生产铱 194 Beta 发射体的放射性核素发生器

• 批准号: 3874417
• 负责人: O A GANSOW
• 金额: --
• 依托单位: DIVISION OF CANCER TREATMENT
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3874417
• 关键词: beta radiation; biomedical equipment safety; clinical biomedical equipment; gamma radiation; iridium; neoplasm /cancer radiodiagnosis; neoplasm /cancer radionuclide therapy; neutron radiation; nuclear medicine; osmium; radiation dosage; radionuclide imaging /scanning; radionuclides; radiopharmacology; radiotracer; beta radiation; biomedical equipment safety; clinical biomedical equipment; gamma radiation; iridium; neoplasm /cancer radiodiagnosis; neoplasm /cancer radionuclide therapy; neutron radiation; nuclear medicine; osmium; radiation dosage; radionuclide imaging /scanning; radionuclides; radiopharmacology; radiotracer

The project investigates the design, manufacturing, testing, and use of a novel radionuclide generator for biomedical applications. The generator has a long shelf-half-life, many years, and produces a 20-hour radionuclide daughter which emits high-energy beta particles that have suitable characteristics for labelling proteins through bifunctional chelates. In the 194-Os/1 94-Ir generator containing the parent nuclei, 194-Os has a halflife of 6.0 years which beta-decays, EmaxB=100 KeV, to the 19.15-hour 194-Ir daughter. The 194-Ir daughter decays with the emission of 2.2 MeV beta particles to the ground state of 194-Pt (86%) and to the 328.5 KeV first excited state with emission of 1.9 MeV beta particles (9.2%). There is a 328.5 KeV gamma-ray which follows the decay of 194-Ir with 13% absolute aboundance. The absence of high intensity gamma-rays in the decay of 194-Ir, with the exception to the 328.5 KeV, makes this beta emitter nuclei very attractive from the point of view of dosimetric considerations. On the other hand, the presence of 328.5 KeV gamma-rays makes 194-Ir a superior nuclei to 90-Y for tumor imaging. This year, Dr. Mirzadeh moved from the NIH to Oak Ridge National Laboratory where he has now completed work on the lridium-194 radionuclidic generator.

该项目研究了设计，制造，测试和使用 用于生物医学应用的新型放射性核素发生器。发电机具有 长时间寿命，多年，并产生20小时的放射性核素 发出合适的高能量β颗粒的女儿 通过双功能螯合物标记蛋白质的特征。 在包含父核的194-OS/1 94-IR发电机中，194-OS具有 半衰期为6。0年的Beta-Depays，Emaxb = 100 KeV，到19.15小时 194-Ir女儿。 194-Ir的女儿发射2.2 MEV腐烂 Beta颗粒至194-PT（86％）和328.5 KEV的基态粒子 首次激发态，排放1.9 MeVβ颗粒（9.2％）。那里 是328.5 KEV Gamma-ray，遵循194-IR的衰减，占13％ 绝对宽度。衰减中没有高强度伽马射线 除328.5 keV的例外，194-ir的企业使此Beta发射器 从剂量计的角度来看，核非常有吸引力。 另一方面，存在328.5 kev伽马射线的存在使194-ir a 用于肿瘤成像的上核至90-Y。 今年，Mirzadeh博士从NIH搬到了橡树岭国家实验室 他现在已经完成了Lridium-194 Radionuclidic Generator的工作。